57th ASH Annual Meeting and Exposition (December 5-8, 2015): 802. Chemical Biology and Experimental Therapeutics

Chemical Biology and Experimental Therapeutics Oral and Poster Abstracts
Oral

W311EFGH, Level 3 (Orange County Convention Center)

Moderators:

Yana Pikman, MD, Dana-Farber Cancer Institute and Boston Children's Hospital and Cristina E. Tognon, PhD, Oregon Health and Science University

Disclosures:

No relevant conflicts of interest to declare.

4:30 PM

865

Identification of Effective Targeted Drug Combinations Using Functional Ex Vivo Screening of Primary Patient Specimens

Stephen E Kurtz, PhD¹^*, Elie Traer, MD, PhD², Jakki Martinez¹^*, Andrew Park¹^*, Jake Wagner¹^*, Ravi Pandya, PhD³^*, William Bolosky, PhD³^*, Brian J. Druker, MD² and Jeffrey W. Tyner, PhD⁴

¹Knight Cancer Institute, Oregon Health & Science University, Portland, OR
²Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
³Research, Microsoft, Redmond, WA
⁴Knight Cancer Institute, Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR

4:45 PM

866

The Pro-Inflammatory Cytokine Interleukin-1 Is Essential for Clonal Expansion and Disease Progression in Acute Myeloid Leukemia

Alyssa Carey, BS¹^*, Megan M Cleary, B.S., B.A.¹^*, David K Edwards V, B.A., B.S.², Christopher A. Eide^1,3^*, Elie Traer, MD, PhD¹, Shannon K. McWeeney, PhD⁴^*, Jeffrey W. Tyner, PhD², Grover C. Bagby, M.D.^1,5, Brian J. Druker, MD^1,3 and Anupriya Agarwal, PhD¹

¹Knight Cancer Institute, Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR
²Knight Cancer Institute, Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR
³Howard Hughes Medical Institute, Portland, OR
⁴Department of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR
⁵Portland VA Medical Center, Portland, OR

5:00 PM

867

JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML

Riikka Karjalalainen¹^*, Tea Pemovska¹^*, Muntasir Mamun Majumder¹^*, Bhagwan Yadav¹^*, Jing Tang¹^*, Mika Kontro²^*, Bjørn Gjertsen, MD, PhD³, Alun Parsons¹^*, Minna Suvela¹^*, Kimmo Porkka²^*, Tero Aittokallio¹^*, Olli Kallioniemi¹^*, Krister Wennerberg¹^*, Jonathan Knowles¹^* and Caroline Heckman¹

¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
²Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
³Department of Clinical Science, University of Bergen, Bergen, Norway

5:15 PM

868

Cancer-Selective Targeting of the NF-κB Survival Pathway in Multiple Myeloma with the GADD45β/MKK7 Inhibitor, DTP3

Laura Tornatore¹^*, Gary Acton²^*, Nigel Adams³^*, Elizabeth A Campbell⁴^*, James Kelly⁵^*, Richard M Szydlo, BSc, PhD⁶^*, Mike Tarbit⁷^*, Salina Bannoo¹^*, Daniel D'Andrea¹^*, Daria Capece¹^*, Annamaria Sandomenico⁸^*, Julian Dyson¹^*, Antonio Leonardi⁹^*, Christoph Driessen¹⁰^*, Menotti Ruvo¹¹^*, Ishara Anees¹²^*, Metod Oblak¹³^*, Sheena Quaid¹⁴^*, Magda J Al-Obaidi¹³^*, Holger Auner¹^*, Reuben Benbenjamin¹⁵^*, Richard S Kaczmarski¹⁶, Martin F Kaiser¹⁷^*, Atul Mehta¹⁸, Heather E Oakervee¹⁹, Stephen A Schey²⁰, Ashutosh Wechalekar²¹, Jane F. Apperley, MD²² and Guido Franzoso²³^*

¹Imperial College London, London, United Kingdom
²Sunshine Clinical Ltd, Surrey, United Kingdom
³In2Phase Ltd, Welwyn Garden City, United Kingdom
⁴C&C Management Consulting Ltd, Exmouth, United Kingdom
⁵Alpha Preclinical Consultancy, Halifax, United Kingdom
⁶Centre for Haematology, Imperial College, London, United Kingdom
⁷Independent Consultant, Royston, United Kingdom
⁸University of Naples ‘‘Federico II, Naples, Italy
⁹11Department of Molecular Medicine and Medical Biotechnologies, University of Naples ‘‘Federico II, Naples, Italy
¹⁰Department of Oncology/Hematology, Kantonsspital St. Gallen, St.Gallen, Swaziland
¹¹Institute of Biostructures and Bioimages, National Research Council and CIRPeB, Naples, Italy
¹²Hillingdon Hospitals NHS Foundation Trust, London, United Kingdom
¹³West Middlesex University Hospital, London, United Kingdom
¹⁴Ealing Hospital, London, United Kingdom
¹⁵Kings College, London, United Kingdom
¹⁶Hillingdon Hospitals NHS Foundation Trust, london, United Kingdom
¹⁷Centre for Myeloma Research, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
¹⁸Royal Free Hospital and University College Medical School, London, United Kingdom
¹⁹Barts Health NHS Trust, London, United Kingdom
²⁰Department of Haemato-oncology, King's College London, London, United Kingdom
²¹University College London Medical School, National Amyloidosis Centre, London, United Kingdom
²²Haematology Department, Hammersmith Hospital (Imperial College Healthcare NHS Trust), London, United Kingdom
²³Centre for Cell Signalling and Inflammation, Imperial College London, London, United Kingdom

5:30 PM

869

3D Modeling of Novel Transforming JAK Mutations in T-Cell Acute Lymphoblastic Leukemia Reveals Altered Pseudokinase-Kinase Domain Interactions That Result in Constitutive JAK Kinase Activity

Kirsten Canté-Barrett, PhD¹, Joost CM Uitdehaag, PhD²^*, Jessica GCAM Buijs-Gladdines¹^*, Wilco K Smits¹^*, Rogier C Buijsman, PhD²^*, Guido JR Zaman, PhD²^*, Rob Pieters, MD, PhD^1,3 and Jules PP Meijerink, PhD¹

¹Department of Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
²Netherlands Translational Research Center B.V., Oss, Netherlands
³Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands

5:45 PM

870

Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML

Lina Benajiba¹^*, Florence Wagner, PhD²^*, Linda Ross, PhD¹^*, Ilene Galinsky, ANP³, Daniel J. DeAngelo, MD, PhD³, Jennifer Gale⁴^*, Jen Pan, PhD⁴^*, Yan-Lin Zhang, PhD⁴^*, Joshua Sacher, PhD⁴^*, Michel Weiwer, PhD⁴^*, Richard M. Stone, MD³, Edward Holson, PhD²^* and Kimberly Stegmaier, MD⁵

¹Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
²Stanley Center for Psychiatric Research, Broad Institute, Cambridge
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴Broad Institute, Cambridge
⁵Department of Pediatric Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, MA

See more of: Chemical Biology and Experimental Therapeutics
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

802.O1.6 802. Chemical Biology and Experimental Therapeutics